SCHEMBL3205875

SCHEMBL3205875

CC(C)=COC(=O)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.38
TDP1 Q9NUW8 2/20 0.32
ALDH1A1 P00352 2/20 0.32
ALOX15 P16050 1/20 0.31
MIF P14174 1/20 0.31
ELANE P08246 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019997 0.82 TSHR (0.37) TSHRTDP1ALDH1A1ALOX15
SCHEMBL12729820 0.78 TSHR (0.34) TSHR
SCHEMBL28634801 0.77 TSHR (0.42) TSHRTDP1ALDH1A1
SCHEMBL9545155 0.75 MIF (0.33) TSHRMIFELANE
SCHEMBL9545151 0.75 MIF (0.33) TSHRMIFELANE
SCHEMBL7697795 0.73 ALDH1A1 (0.33) TSHRTDP1ALDH1A1
SCHEMBL9724371 0.73 TSHR (0.35) TSHRTDP1ALDH1A1ALOX15
SCHEMBL28251477 0.73 ALDH1A1 (0.44) TSHRTDP1ALDH1A1ALOX15MIF
SCHEMBL524350 0.72
SCHEMBL445941 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 US disclosed
EP-2038279-A2 SUBSTITUTED PYRAZOLO [1,5- ALPHA] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE Avigen, Inc. (US) 2009-03-25 EP disclosed
US-20080070912-A1 Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use AVIGEN, INC. (US) 2008-03-20 US disclosed
WO-2007146087-A2 SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 TSHR 2542/4885TDP1 816/4885ALDH1A1 773/4885
US-20080070912-A1 Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use PNPO, PDXK, P2RX5 TSHR 2585/4885TDP1 869/4885ALDH1A1 549/4885
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 TSHR 2542/4885TDP1 816/4885ALDH1A1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.